The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic ...

BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape Precision medicine has become a dominant theme in the treatment of biliary tract cancers (BTCs). Although prognosis ...

Zanidatamab-hrii received FDA accelerated approval for HER2-positive biliary tract cancer, showing a 52% objective response rate in the HERIZON-BTC-01 trial. Biliary tract cancers represent 3% of ...

Academic-center care was independently associated with higher complete oncologic resection rates and improved overall survival versus nonacademic facilities after adjustment for age, comorbidity, and ...

Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early ...

Compass Therapeutics (CMPX) is back on investors’ radar after fresh analysis of the biliary tract cancer market highlighted its lead candidate CTX-009 as a key emerging therapy in this growing ...

Findings showed that pembrolizumab plus chemotherapy reduced the risk of death by 17% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ® (pembrolizumab) ...

Rachna T. Shroff, MD, addresses the impact of health disparities in the treatment outcomes of patients with cancer. Specifically discussing patients with biliary tract cancer, Dr Shroff focuses ...

Biliary tract cancer is increasing in incidence and mortality across Europe, with more people under the age of 60 years old now impacted by the disease. However, despite this, knowledge about these ...

Results showed the ORR was 17.1% in the tovecimig plus paclitaxel arm compared with 5.3% in the paclitaxel alone arm. Topline data were announced from a phase 2/3 trial evaluating tovecimig in ...

Biliary tract cancers, including cholangiocarcinoma and gallbladder carcinoma, represent a heterogeneous group of malignancies with rising global incidence and persistent dismal prognoses. Research in ...

At its April 2025 meeting, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) gave a conditional marketing authorization for Ziihera (zanidatamab, Jazz ...